July 2024: The biggest private biotech investments
This issue of our newsletter is supported by Global Bio-India 2024.
In July 2024, the top three private biotech investments went to: Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio.
The cardiovascular company Cardurion gained the top spot after its impressive $260 million series B round.
However, around the world, oncology and central nervous system players attracted the biggest funding rounds overall.
And looking at our month-to-month comparison, although there were slightly fewer funding rounds last month than in June, more money was raised overall – $92 million more, in fact.
To find out more, read the full article: “The biggest private biotech investments in July 2024”
A MESSAGE FROM OUR SPONSOR GLOBAL BIO-INDIA 2024
Join us at Global Bio-India 2024: September 12-14 in New Delhi
Be a part of the Global Bio-India 2024, a mega international congregation of biotechnology stakeholders organized by the Dept. of Biotechnology, Govt. of India along with Biotechnology Industry Research Assistance Council (BIRAC) from September 12-14 in New Delhi with a focus on ‘Biotech Innovation Ecosystem’ and ‘Bio-manufacturing’.
Recommended by LinkedIn
🔥 More noteworthy articles from this week:
CureVac’s recent deal with GSK – worth up to $1.57 billion (€1.45 billion) – has marked a major turnaround for the company after it failed to develop a COVID-19 vaccine in 2021. This article explores CureVac’s challenges, strategies, and the pivotal $1.57 billion deal that reshaped its future.
Despite being approved in the U.S. last year, European regulators have refused to market Eisai and Biogen’s Alzheimer’s drug Leqembi in Europe, as the European Medicines Agency (EMA) recommended against selling Leqembi in the region, citing that the risk the drug posed outweighed the benefit.
Epigenetics is the study of changes in organisms caused by modification of gene expression. By targeting epigenetic mechanisms, epigenetic therapies alter gene expression patterns to treat diseases. In this article, we take a look at six epigenetics biotech companies that are significant as well as up-and-coming players in the industry.
A new collaboration between AI drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. On this episode, we had a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a wide range of subjects including drug discovery, undruggable targets, the collaboration with the University of Toronto, and more.
With a comprehensive suite of services tailored to support cell and gene therapies (CGT) research and development, Cryoport Systems is expanding its presence in Europe to meet escalating market demands. As demand surges, overcoming challenges becomes pivotal, highlighting the imperative of strategic collaborations with industry-leading partners as the CGT market continues to grow at an unprecedented pace.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.